Patents Examined by Kahsay Habte
-
Patent number: 11730714Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.Type: GrantFiled: December 14, 2018Date of Patent: August 22, 2023Assignee: NMD PHARMA A/SInventors: Thomas Holm Pedersen, Lars J. S. Knutsen, Nicholas M. Kelly, Martin Broch-Lips, Claus Elsborg Olesen, Marc Labelle, Ole Bækgaard Nielsen, Rajesh Kumar
-
Patent number: 11731939Abstract: The indole-based chalcone compounds are antibacterial agents. The emergence of drug-resistant bacteria calls for constant development of new antibacterial agents with the aim of generating medicaments that are potent against drug sensitive and resistant bacteria and are well tolerated. The present compounds are not only new, but have very valuable antimicrobial properties. These compounds showed a broad spectrum of activity against gram-positive and gram-negative bacteria, as well tuberculosis mycobacteria. They also showed potent activity against drug-resistant bacteria, such as MRSA and VRSA. The molecular target of these compounds was identified as DNA Gyrase B. Based on their pharmacological profiles, the present compounds may find important clinical applications for severe infectious diseases and tuberculosis.Type: GrantFiled: March 7, 2023Date of Patent: August 22, 2023Assignee: KING FAISAL UNIVERSITYInventors: Christophe Tratrat, Michelyne Haroun
-
Patent number: 11731948Abstract: Improved processes for producing high purity acesulfame potassium. In one embodiment, the process comprises the steps of contacting a solvent, e.g., dichloromethane, and a cyclizing agent, e.g., sulfur trioxide, to form a cyclizing agent composition and reacting an acetoacetamide salt with the cyclizing agent in the composition to form a cyclic sulfur trioxide adduct. The contact time is less than 60 minutes. The process also comprises forming from the cyclic sulfur trioxide adduct composition a finished acesulfame potassium composition comprising non-chlorinated, e.g., non-chlorinated, acesulfame potassium and less than 35 wppm 5-halo acesulfame potassium, preferably less than 5 wppm.Type: GrantFiled: March 19, 2021Date of Patent: August 22, 2023Assignee: Celanese International CorporationInventors: Christoph Mollenkopf, Peter Groer, Arvind Yadav
-
Patent number: 11724993Abstract: Compositions and processes for producing high purity acesulfame potassium are described. One process comprises the steps of forming a cyclic sulfur trioxide adduct; hydrolyzing the cyclic sulfur trioxide adduct to form an acesulfame-H composition comprising acesulfame-H; neutralizing the acesulfame-H in the acesulfame-H composition to form a crude acesulfame potassium composition comprising acesulfame potassium and less than 2800 wppm acetoacetamide-N-sulfonic acid, wherein the neutralizing step is conducted or maintained at a pH at or below 11.0; and treating the crude acesulfame potassium composition to form the finished acesulfame potassium composition comprising acesulfame potassium and less than 37 wppm acetoacetamide-N-sulfonic acid.Type: GrantFiled: March 19, 2021Date of Patent: August 15, 2023Assignee: Celanese International CorporationInventors: Christoph Mollenkopf, Peter Groer, Arvind Yadav
-
Patent number: 11724994Abstract: A process for producing acesulfame potassium, the process comprising the steps of providing a cyclizing agent composition comprising a cyclizing agent and a solvent and having an initial temperature, cooling the cyclizing agent composition to form a cooled cyclizing agent composition having a cooled temperature less than 35° C., reacting an acetoacetamide salt with the cyclizing agent in the cooled cyclizing agent composition to form a cyclic sulfur trioxide adduct composition comprising cyclic sulfur trioxide adduct; and, forming from the cyclic sulfur trioxide adduct in the cyclic sulfur trioxide adduct composition the finished acesulfame potassium composition comprising non-chlorinated acesulfame potassium and less than 39 wppm 5-chloro-acesulfame potassium. The cooled temperature is at least 2° C. less than the initial temperature.Type: GrantFiled: March 19, 2021Date of Patent: August 15, 2023Assignee: Celanese International CorporationInventors: Christoph Mollenkopf, Peter Groer, Arvind Yadav
-
Patent number: 11725011Abstract: The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.Type: GrantFiled: November 20, 2020Date of Patent: August 15, 2023Assignees: THE GENERAL HOSPITAL CORPORATION, DANA-FARBER CANCER INSTITUTE, INC., THE BROAD INSTITUTE, INC.Inventors: Nathanael S. Gray, Yanke Liang, Hwan Geun Choi, Thomas Sundberg, Alykhan Shamji, Ramnik Xavier, David E. Fisher, Nisma Mujahid
-
Patent number: 11725001Abstract: The present disclosure relates to a compound derivative containing a 6-7 bicyclic ring and use thereof. The compound according to the present invention can be effectively used in the prevention or treatment of diseases caused by PRMT5 by acting as a PRMT5 inhibitor.Type: GrantFiled: July 19, 2021Date of Patent: August 15, 2023Assignee: SK BIOPHARMACEUTICALS CO., LTD.Inventors: Yong Je Shin, Jin Hee Kim, Jun Lee, Sook Kyung Park, Ho Yeon Lee, Hyun Suk Choi, Se Hyuk Kim, Eun Ji Kang, Ho Youl Lee, Soo Yeon Jung
-
Patent number: 11718594Abstract: Compositions and processes for producing high purity acesulfame potassium are described. One process comprises the steps of providing a crude acesulfame potassium composition comprising acesulfame potassium and acetoacetamide, concentrating the crude acesulfame potassium composition to form a water stream and an intermediate acesulfame potassium composition comprising acesulfame potassium and less than 33 wppm acetoacetamide, and separating the intermediate acesulfame potassium composition to form the finished acesulfame potassium composition comprising acesulfame potassium and less than 33 wppm acetoacetamide. The concentrating step is conducted at a temperature below 90° C. and the separating step is conducted at a temperature at or below 35° C.Type: GrantFiled: March 19, 2021Date of Patent: August 8, 2023Assignee: Celanese International CorporationInventors: Christoph Mollenkopf, Peter Groer, Arvind Yadav
-
Patent number: 11718595Abstract: Compounds that inhibit p38? MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.Type: GrantFiled: June 16, 2021Date of Patent: August 8, 2023Assignee: University of Maryland, BaltimoreInventors: Paul S. Shapiro, Alexander D. Mackerell, Jr., Jeffrey D. Hasday, Steven Fletcher
-
Patent number: 11713327Abstract: The present invention relates to compounds of formula (I), ab (I), wherein R1 to R3 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.Type: GrantFiled: June 11, 2019Date of Patent: August 1, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Fabian Dey, Buyu Kou, Haixia Liu, Hong Shen, Xiaoqing Wang, Weixing Zhang, Zhisen Zhang, Zhiwei Zhang, Wei Zhu
-
Patent number: 11708363Abstract: Disclosed herein relates to organic synthesis, and more particularly to a method for preparing a key intermediate for the synthesis of statins. The key intermediate is 2-[(4R,6S)-6-[(benzo[d]thiazol-2-ylthio)methyl]-2,2-disubstituted-1,3-dioxan-4-yl] acetate of formula (I): where R1 is a C1-C8 alkyl group, a C3-C8 cycloalkyl group, a monosubstituted or polysubstituted aryl group, or monosubstituted or polysubstituted aralkyl group; R2 is hydrogen, or monosubstituted or polysubstituted C1-C3 alkyl group, or halogen; and R3 and R4 are each independently a C1-C5 alkyl group, a C3-C7 cycloalkyl group, a C3-C7 cycloalkenyl group, a C1-C3 alkoxy group, a C6-C10 aryl group, or C7-C12 aralkyl group. In the method, a halomethyl compound and a thiol reagent are subjected to nucleophilic substitution in an organic solvent to synthesize a thioether, which then undergoes ketal exchange reaction with a carbonyl compound (V) in the presence of an organic acid to obtain a target product.Type: GrantFiled: September 28, 2021Date of Patent: July 25, 2023Assignee: Fudan UniversityInventors: Fener Chen, Dang Cheng, Minjie Liu, Zedu Huang, Yuan Tao, Jiaqi Wang
-
Patent number: 11702413Abstract: A comonomer comprising: wherein W is selected from the group consisting of: S, Se, O, and N-Q; and Q is selected from the group consisting of: a straight-chain or branched carbyl, silyl, or hydrocarbyl, a branched or cyclic alkyl with 1 to 30 atoms, a fused substituted aromatic ring, and a fused unsubstituted aromatic ring. In this comonomer, A and B are independently selected from the group consisting of: H, Br, an aryl group, and a heteroaryl group.Type: GrantFiled: August 26, 2020Date of Patent: July 18, 2023Assignee: Phillips 66 CompanyInventors: Hualong Pan, Kathy Woody, Brian J. Worfolk
-
Patent number: 11702403Abstract: Disclosed are compounds that activate excitatory amino acid transporter 2 (EAAT2), as well as methods of using these compounds to treat or preventing diseases, disorders, and conditions associated with glutamate excitotoxicity.Type: GrantFiled: June 4, 2019Date of Patent: July 18, 2023Assignees: OHIO STATE INNOVATION FOUNDATION, THE BRIGHAM AND WOMAN'S HOSPITAL, INC.Inventors: Kevin Hodgetts, Chien-Liang Glenn Lin
-
Patent number: 11702409Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.Type: GrantFiled: December 17, 2020Date of Patent: July 18, 2023Assignee: NOVARTIS AGInventors: Simona Cotesta, Marc Gerspacher, Catherine Leblanc, Edwige Liliane Jeanne Lorthiois, Bo Liu, Rainer Machauer, Robert Mah, Christophe Mura, Pascal Rigollier, Nadine Schneider, Stefan Stutz, Andrea Vaupel, Nicolas Warin, Rainer Wilcken
-
Patent number: 11702416Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.Type: GrantFiled: June 4, 2021Date of Patent: July 18, 2023Assignees: Incyte Corporation, Incyte Holdings CorporationInventors: Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
-
Patent number: 11702419Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.Type: GrantFiled: March 15, 2021Date of Patent: July 18, 2023Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuya Oguro, Shigemitsu Matsumoto, Takeshi Wakabayashi, Norihito Tokunaga, Taku Kamei, Mitsuhiro Ito, Satoshi Mikami, Masaki Seto, Shinji Morimoto, Shinji Nakamura, Sachie Takashima, Masataka Murakami, Masaki Daini, Makoto Kamata, Minoru Nakamura, Yasufumi Wada, Hiroyuki Kakei, Kazuaki Takami, Taisuke Tawaraishi, Jumpei Aida, Kouichi Iwanaga, Satoshi Yamamoto
-
Patent number: 11702406Abstract: Certain antiviral compounds, pharmaceutical compositions, and methods related thereto are disclosed.Type: GrantFiled: December 12, 2022Date of Patent: July 18, 2023Assignee: ASCLETIS BIOSCIENCE CO., LTD.Inventor: Jinzi J. Wu
-
Patent number: 11697658Abstract: The present disclosure relates to the technical field of drug synthesis, in particular to a method for preparing lornoxicam. The method includes the following steps: using 6-chloro-4-hydroxy-2-methyl-2-H-thieno[2,3-e]-1,2-thiazine methyl carboxylate-1,1-dioxide and 2-aminopyridine as raw materials, and xylene as a solvent; mixing the raw material and solvent, and adding a stabilizer, to obtain a mixture; subjecting the mixture to an ammonolysis; cooling the resulting reactant; conducting a vacuum concentration to remove the solvent; adding an organic solvent and slurrying, and filtering, to obtain a crude lornoxicam; and refining the crude lornoxicam to obtain the lornoxicam. In the present disclosure, p-toluenesulfonic acid is used as a stabilizer to reduce the reaction temperature and promote the reaction to proceed forward, thereby improving the quality and yield of the product.Type: GrantFiled: July 23, 2021Date of Patent: July 11, 2023Assignee: Beijing Jincheng Taier Pharmaceutical Co., Ltd.Inventors: Zhen Liu, Dongye Xing, Zhongzheng Zhang, Jie Li, Yangong Han, Yali Cui, Liru Wang, Hongliang Liu, Yan Mi, Li Li, Jingang Tang, Yi Kang
-
Patent number: 11697647Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.Type: GrantFiled: November 5, 2021Date of Patent: July 11, 2023Assignee: Eli Lilly and CompanyInventors: Gabrielle R. Kolakowski, Erin D. Anderson, Steven W. Andrews, Christopher Pierre Albert Jean Boldron, Kevin R. Condroski, Thomas C. Irvin, Manoj Kumar, Elizabeth A. McFaddin, Megan L. McKenney, Johnathan Alexander McLean, Tiphaine Mouret, Michael J. Munchhof, Thomas Pierre Dino Pancaldi, Michael Alexander Pilkington-Miksa, Marta Pinto
-
Patent number: 11691963Abstract: The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.Type: GrantFiled: May 5, 2021Date of Patent: July 4, 2023Assignee: Ajax Therapeutics, Inc.Inventors: Craig E. Masse, Jeremy R. Greenwood, Sayan Mondal, Jiayi Xu, Phani Ghanakota, Fiona Michelle McRobb, Nicholas Boyles